FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  McKelligon Brian					<u>A</u>	2. Issuer Name and Ticker or Trading Symbol Akoya Biosciences, Inc. [ AKYA ]									k all applica Director Officer (	tionship of Reportin all applicable) Director Officer (give title		10% Ov	wner
(Last) (First) (Middle) 100 CAMPUS DRIVE,6TH FLOOR						Date of Earliest Transaction (Month/Day/Year) 02/23/2023								below) below)  President/CEO					
(Street)  MARLB  (City)	OROUGH (S		01762 (Zip)		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line)	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,		Transaction Disposed Code (Instr.			ties Acquired (A) or I Of (D) (Instr. 3, 4 and I			5. Amoun Securities Beneficia Owned Fo	s lly ollowing	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)		ce	Transacti (Instr. 3 a	ion(s)			(moti. 4)	
Common Stock 02/23/				3/202	/2023		A		80,000	0,000 <sup>(1)</sup> A \$		).00 <sup>(2)</sup>	160,000			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Ti	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		•	7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisabl			Title	Amou or Numb of Sha	oer		(Instr. 4)		۶)	
Employee Stock Option (Right to Buy)	\$12.3	02/23/2023			A		160,000		(3)		02/23/2033	Common Stock	160,	.000	\$0.00	160,00	00	D	

## **Explanation of Responses:**

- 1. The restricted stock units shall vest in four (4) equal annual installments beginning on the first anniversary of the grant date and on each anniversary thereafter.
- 2. Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
- 3. The options shall vest as follows: twenty-five percent (25%) shall vest on the first anniversary of the grant date with the remainder vesting in 36 equal monthly installments beginning on March 23, 2024.

/s/ Brian McKelligon

02/27/2023

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.